New clinical trial testing amivantamab for patients who progressed on RET therapies:
A Phase 1 / 2 Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors (TKIs).
NCT05845671. In many cases patients who become resistant to TKI therapies including RET inhibitors present increased activation of the epidermal growth factor receptor (ERBB) or mesenchymal-epithelial transition (cMet) as a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure from the TKI therapy. The new clinical trial lead by Dr. Tejas Patil from University of Colorado, study the effects of amivantamab, a bispecific antibody that binds to the extracellular domains of EGFR and MET in patients who progressed on TKI therapies including RET therapies.
- Participant has locally advanced (unresectable) or metastatic NSCLC with a known RET fusion. Participants must have clinical progression on at least one prior RET therapy.
- They must be on a RET inhibitor at the same dose for at least 3 months prior to enrolling in this study.
- RET inhibitors that will be considered include but not limited to selpercatinib and pralsetinib.
- The patient cannot have received an EGFR TKI (e.g. osimertinib, afatinib), EGFR- directed monoclonal antibody (e.g. cetuximab), MET-inhibitor (e.g., tepotinib, capmatinib, telisotuzumab vedotin, etc.) at any point prior to study entry.
More inclusion criteria details on the study web: https://classic.